BUSINESS
Ono Licenses MALT1 Inhibitor for Blood Cancer Treatments from Takeda Spin-Off Chordia
Ono Pharmaceutical will obtain the exclusive worldwide rights to develop, manufacture, and commercialize Chordia Therapeutics’ mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor CTX-177 and its related compounds, they said on December 15. Under the terms of the deal,…
To read the full story
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





